Poster session 13

Programm

• 15:30 – 15:35 3 Min. 2 Min.

  • ePoster
  • P137a

  Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study

  • Saygin Gonderten (Dubai/ AE)

   Migraine
• 15:35 – 15:40 3 Min. 2 Min.

  • ePoster
  • P138

  Patterns of use of monoclonal antibodies for the preventive treatment of migraine: Results from the OVERCOME (EU) study

  • Saygin Gonderten (Dubai/ AE)
  • Stefan Evers (Münster/ DE)

   Migraine
• 15:40 – 15:45 3 Min. 2 Min.

  • ePoster
  • P139

  Cardiovascular risk factors and migraine: Results from the population-based Rotterdam study

  • Linda Al-Hassany (Rotterdam/ NL)

   Epidemiology, Migraine
• 15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P141

  Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials

  • Krisztian Nagy (Budapest/ HU)

   Migraine
• 15:50 – 15:55 3 Min. 2 Min.

  • ePoster
  • P142

  Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)

  • Krisztian Nagy (Budapest/ HU)

   Migraine
• 15:55 – 16:00 3 Min. 2 Min.

  • ePoster
  • P143

  Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)

  • Richard B. Lipton (Bronx, NY/ US)

   Migraine
• 16:00 – 16:05 3 Min. 2 Min.

  • ePoster
  • P144

  Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis.

  • Pablo Irimia (Pamplona/ ES)

   Migraine
• 16:05 – 16:10 3 Min. 2 Min.

  • ePoster
  • P145

  Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months

  • Alicia Alpuente (Barcelona/ ES)

   CGRP inhibitors in the clinic, Migraine
• 16:10 – 16:15 3 Min. 2 Min.

  • ePoster
  • P146

  Mapping Migraine Minds: A cross-sectional survey to compare the difference in the level of treatment expectations and satisfaction for migraine among Indian male & female patients

  • Sneha Thakur (Mumbai/ IN)

   Epidemiology, Migraine
• 16:15 – 16:20 3 Min. 2 Min.

  • ePoster
  • P147

  Migraine, chronic neck pain and endurance muscle cervical test – a controlled study

  • Amanda Rodrigues (Ribeirão Preto/ BR)

   Migraine, Multidisciplinary clinical assessments
• 16:20 – 16:25 3 Min. 2 Min.

  • ePoster
  • P150

  Onabotulinum toxinA for unremitting chronic migraine: assessment of muscle function and strength, efficacy and safety after 10 years of continuous treatment.

  • Guy Pierre Boudreau (Montreal/ CA)

   Migraine
• 16:25 – 16:30 3 Min. 2 Min.

  • ePoster
  • P151

  Long-term Effectiveness and Safety of Erenumab in patients with Migraine: a Systematic Review and Single-Arm Meta-analysis

  • Fernanda Ferreira Bomtempo (Belo Horizonte/ BR)

   CGRP inhibitors in the clinic, Migraine
• 16:30 – 16:35 3 Min. 2 Min.

  • ePoster
  • P152

  Prospective evaluation of migraine premonitory symptoms during the 30 days period

  • Kirill Skorobogatykh (Moscow/ RU)

   Data science in research and digital medicine, Migraine
• 16:35 – 16:40 3 Min. 2 Min.

  • ePoster
  • P153

  Prevalence of sinonasal symptoms in migraine without aura (results from Migraine in Poland - a nationwide cross-sectional survey)

  • Marcin Straburzyński (Olsztyn/ PL)

   Migraine
• 16:40 – 16:45 3 Min. 2 Min.

  • ePoster
  • P149

  Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study

  • Robert Croop (New Haven/ US)

   CGRP inhibitors in the clinic, Migraine
• 16:45 – 16:50 3 Min. 2 Min.

  • ePoster
  • P148

  Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

  • Jessica Ailani

   CGRP inhibitors in the clinic, Migraine
• 16:50 – 16:55 3 Min. 2 Min.

  • ePoster
  • P136a

  Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

  • Robert Croop (New Haven/ US)

   CGRP inhibitors in the clinic, Migraine
• 16:55 – 17:00 3 Min. 2 Min.

  • ePoster
  • P140

  A prospective evaluation of neurological presentations to a National Neuro-Behçet Clinic in the UK- Migraine is the commonest neurological complaint in Behçet's disease

  • Mona Ghadiri-Sani (Liverpool/ GB)

   Migraine, Secondary headaches